<DOC>
	<DOCNO>NCT01183897</DOCNO>
	<brief_summary>The purpose study see find effect , good and/or bad , combination 3F8 GM-CSF patient cancer .</brief_summary>
	<brief_title>3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid Primary Refractory Neuroblastoma Bone Marrow</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Diagnosis NB define ) histopathology ( confirm MSKCC Department Pathology ) , b ) BM metastases MIBGavid lesion ( ) plus high urine catecholamine level . Highrisk NB define riskrelated treatment guidelines1 International NB Staging System,89 i.e. , stage 4 ( age ) without ( &gt; = 18 month age ) MYCN amplification MYCNamplified stage 4S . Patients primary refractory disease limit BM , i.e. , highrisk NB ( define ) resistant standard therapy , evidence incomplete response BM , measurable MIBGavid soft tissue tumor assessable response progressive disease . Signed informed consent indicate awareness investigational nature program . Creatinine &gt; 3.0 mg/dL ALT , AST Alkaline Phosphatase &gt; 5.0 time upper limit normal Bilirubin &gt; 3.0 mg/dL Patients grade 3 high toxicity ( use CTCAE v 4.0 ) relate cardiac , neurological , pulmonary gastrointestinal function determine physical exam . Patients must normal blood pressure age . Progressive disease History allergy mouse protein . Active lifethreatening infection . Human antimouse antibody ( HAMA ) titer &gt; 1000 Elisa units/ml . Inability comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>GM-CSF</keyword>
	<keyword>MAB 3F8</keyword>
	<keyword>RETINOIC ACID ( CIS-9 &amp; 13 )</keyword>
	<keyword>09-161</keyword>
</DOC>